Ignite Creation Date:
2025-12-24 @ 3:14 PM
Ignite Modification Date:
2026-03-04 @ 7:44 PM
Study NCT ID:
NCT04462692
Status:
WITHDRAWN
Last Update Posted:
2021-11-01
First Post:
2020-07-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Observational Study in Children With CLN2 Batten Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009472', 'term': 'Neuronal Ceroid-Lipofuscinoses'}], 'ancestors': [{'id': 'D020271', 'term': 'Heredodegenerative Disorders, Nervous System'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008064', 'term': 'Lipidoses'}, {'id': 'D008052', 'term': 'Lipid Metabolism, Inborn Errors'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}, 'patientRegistry': False}, 'statusModule': {'whyStopped': 'study stopped due to company decision', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2021-03-31', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-10', 'completionDateStruct': {'date': '2023-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-10-25', 'studyFirstSubmitDate': '2020-07-02', 'studyFirstSubmitQcDate': '2020-07-02', 'lastUpdatePostDateStruct': {'date': '2021-11-01', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-07-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-10', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in retinal structure in children with CLN2 Batten disease', 'timeFrame': '96 weeks', 'description': 'As assessed by SD-OCT measures over time.'}], 'secondaryOutcomes': [{'measure': 'Change in visual function', 'timeFrame': '96 weeks', 'description': 'As assessed by visual acuity over time.'}, {'measure': 'Change in visual function', 'timeFrame': '96 weeks', 'description': 'As assessed by pupillary light reflex over time.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['CLN2, Batten Disease'], 'conditions': ['Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)']}, 'descriptionModule': {'briefSummary': 'This is a prospective, longitudinal natural history study to document the progression of ocular manifestations of CLN2 disease among a community-dwelling population of pediatric participants affected by this disease.', 'detailedDescription': 'CLN2 is a rare disease with limited available ocular natural history data. While current standard of care slows motor degeneration, it is not known to treat the ocular manifestations of disease. This study is planned to document, through prospective data collection, ocular disease progression in children with a clinical presentation consistent with CLN2 Batten disease undergoing current standard of care for their condition. No investigational product is administered in this observational study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Children with CLN2 Batten disease undergoing current standard of care for their condition.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nA participant is eligible to be included in the study only if all of the following criteria apply:\n\n1. His or her legal guardian(s) is(are) willing and able to provide them written, signed informed consent.\n2. Has documented diagnosis of CLN2 disease due to TPP1 deficiency, or has a relative clinically diagnosed with CLN2 with the same mutation as the participant\n3. Is currently receiving biweekly ERT treatment with cerliponase alfa\n\nExclusion Criteria:\n\nA participant is excluded from the study if any of the following criteria apply:\n\n1. Has had prior treatment with an adeno-associated virus-based AAV gene therapy\n2. Is currently participating in a clinical trial of investigational product for the treatment of CLN2 disease'}, 'identificationModule': {'nctId': 'NCT04462692', 'briefTitle': 'An Observational Study in Children With CLN2 Batten Disease', 'organization': {'class': 'INDUSTRY', 'fullName': 'REGENXBIO Inc.'}, 'officialTitle': 'A Prospective, Observational Study to Evaluate Ocular Disease Progression in Children With CLN2 Batten Disease', 'orgStudyIdInfo': {'id': 'RGX-381-9101'}}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'REGENXBIO Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}